# Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021

> **NCT02342548** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 188 (actual)

## Conditions studied

- Huntington's Disease

## Interventions

- **DRUG:** 20 mg BID of PF-02545920

## Key facts

- **NCT ID:** NCT02342548
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-02-25
- **Primary completion:** 2017-02-06
- **Final completion:** 2017-02-06
- **Target enrollment:** 188 (ACTUAL)
- **Why stopped:** Study terminated on 15DEC2016 due to study A8241021 showing no significant difference on primary endpoint between PF-02545920 \& placebo. No safety concerns.
- **Last updated:** 2018-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02342548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02342548, "Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02342548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*